Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, cilt.17, ss.404-413, 2016 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17
- Basım Tarihi: 2016
- Doi Numarası: 10.3109/21678421.2016.1167913
- Dergi Adı: AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.404-413
- Anahtar Kelimeler: Cerebrospinal fluid, neurofilament, biomarker, amyotrophic lateral sclerosis, round robin, AMYOTROPHIC-LATERAL-SCLEROSIS, CEREBROSPINAL-FLUID, HEAVY-CHAIN, ALZHEIMERS-DISEASE, LIGHT LEVELS, STANDARDIZATION, PHOSPHOFORMS, DEGENERATION, PROGRESSION, COLLECTION
- İstanbul Üniversitesi Adresli: Evet
Özet
OBJECTIVE: Neurofilaments are leading neurochemical biomarkers for amyotrophic lateral sclerosis (ALS). Here, we investigated the effect of preanalytical factors on neurofilament concentrations in cerebrospinal fluid (CSF) in a reverse round-robin with 15 centers across Europe/U.S. METHODS: Samples from ALS and control patients (5/5 each center, n=150) were analyzed for phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) at two laboratories. RESULTS: CSF pNfH was increased (p<0.05) in ALS in 10 out of 15 centers and NfL in 5 out of 12 centers. The coefficient of variation (CV%) of pNfH measurements between laboratories was 18.7 +/- 19.1%. We calculated a diagnostic cut-off of >568.5pg/mL for pNfH (sensitivity 78.7%, specificity 93.3%) and >1,431pg/mL for NfL (sensitivity 79.0%, specificity 86.4%). CONCLUSION: Values in ALS patients are already comparable between most centers, supporting eventual implementation into clinical routine. However, continuous quality control programs will be necessary for inclusion in the diagnostic work-up.